Treatment Advances in Ovarian Cancer

Cancer Nursing

Volumn 26, Issue 6 SUPPL., 2003, Pages

  Almadrones, Lois A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antitumor agents; Chemotherapy; Investigational treatments; Ovarian cancer; Quality of life therapies

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; ALTRETAMINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 3; LIPOSOME; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; SEROTONIN 3 ANTAGONIST; SODIUM THIOSULFATE; TAXANE DERIVATIVE; TOPOTECAN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CAUSE OF DEATH; CHRONIC DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG TUMOR LEVEL; FEMALE; GENE THERAPY; HAND FOOT SYNDROME; HUMAN; LEUKEMIA; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

EID: 0347627158     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-200312001-00005     Document Type: Conference Paper

References (16)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955.
3. National Comprehensive Cancer Network. Ovarian cancer guideline. Version 1.2002. Available at: http://www.nccn.org. Accessed March 5, 2003.
4. Armstrong DK. Challenges of treating ovarian cancer: first-line and relapse therapy. Oncol Spec Ed. 2001;4:25-29.
5. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002;7(suppl 5):20-28.
6. Latorre A, De Lena M, Catino A, et al. Epithelial ovarian cancer: second-and third-line chemotherapy [review]. Int J Oncol. 2002;21:179-186.
7. Ozols RF. Treatment of recurrent ovarian cancer: increasing options: "recurrent" results [editorial]. J Clin Oncol. 1997;15:2177-2180.
8. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193.
9. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer. 2002;38:57-63.
10. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf. 2001;24:903-920.
11. Dunton CJ. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist. 2002;7(suppl 5):11-19.
12. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
13. de Vries EG, Hamilton TC, Lind M, Dauplat J, Neijt JP, Ozols RF. Advanced ovarian cancer: drug resistance, supportive care, and dose intensity. Ann Oncol. 1993;4(suppl 4):57-62.
14. Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol. 2002;29(suppl 1):32-42.
15. Trimble EL. Innovative therapies for advanced ovarian cancer. Semin Oncol. 2000;27(suppl 7):24-30.
16. Ma J, Samuel J, Kwon GS, Noujaim AA, Madiyalakan R. Induction of antiidiotypic humoral and cellular immune responses by a murine mon-oclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres. Cancer Immunol Immunother. 1998;47:13-20.